Paper

Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia

Published Sep 15, 2006 · H. Lane, Chieh-Liang Huang, Po‐Lun Wu

Biological Psychiatry

163

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCTRigorous JournalHighly Cited

Study Snapshot

Sarcosine or NMDA-glycine site agonists added to clozapine treatment show no improvement in schizophrenia symptoms, suggesting clozapine's unique clinical efficacy and refractoriness to NMDA-enhancing agents.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia

References

Citations